Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma
You may also be interested in...
Asia Spotlight: GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.
GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.
Bristol’s Taxol, Sanofi’s Taxotere Among Latest Victims Of China Price Cuts
China’s NDRC cuts retail ceiling prices on 95 cancer, hematology and immunology drugs, with more cuts expected next year.